dronabinol has been researched along with Alloxan Diabetes in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fenning, AS; Jackson, DJ; Vella, RK | 1 |
| Aydin, S; Beydogan, AB; Bolkent, S; Coskun, ZM; Yanar, K | 1 |
| Bolkent, S; Coskun, ZM | 2 |
| Akkan, AG; Altınok, A; Bolkent, S; Coşkun, ZM; Karaoğlu, K; Özyazgan, S | 1 |
| Amin, R; Andrews, MJ; Czyzyk, TA; Davis, BJ; Haskins, CP; Henderson-Redmond, AN; Mackie, K; Marcus, DJ; Morgan, DJ; Zee, ML | 1 |
| Avraham, Y; Berry, EM; Dagon, Y; Link, G; Mechoulam, R; Zolotarev, O | 1 |
| Haller, VL; Stevens, DL; Welch, SP; Williams, J | 1 |
| Fischer, LJ; Kaminski, NE; Li, X | 1 |
9 other study(ies) available for dronabinol and Alloxan Diabetes
| Article | Year |
|---|---|
Δ
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dronabinol; Hypoglycemic Agents; Lipid Peroxidation; Male; Rats; Rats, Inbred WKY | 2017 |
The effects of delta-9-tetrahydrocannabinol on Krüppel-like factor-4 expression, redox homeostasis, and inflammation in the kidney of diabetic rat.
Topics: Animals; Biomarkers; Cannabinoid Receptor Agonists; Cytokines; Diabetes Mellitus, Experimental; Dronabinol; Gene Expression Regulation; Homeostasis; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Oxidation-Reduction; Rats; Streptozocin | 2019 |
Biochemical and immunohistochemical changes in delta-9-tetrahydrocannabinol-treated type 2 diabetic rats.
Topics: Animals; Blood Glucose; Cannabinoid Receptor Agonists; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dronabinol; Drug Evaluation, Preclinical; Glucagon; Insulin; Islets of Langerhans; Lipid Metabolism; Lipoproteins; Male; Rats, Sprague-Dawley | 2014 |
Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ⁹-THC.
Topics: Animals; Body Weight; Cannabinoid Receptor Agonists; Catalase; Diabetes Mellitus, Experimental; Dronabinol; Glutathione; Islets of Langerhans; Male; Niacinamide; Oxidative Stress; Pancreas; Pancreatic Ducts; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Streptozocin; Superoxide Dismutase | 2014 |
Δ9-tetrahydrocannabinol treatment improved endothelium-dependent relaxation on streptozotocin/nicotinamide-induced diabetic rat aorta.
Topics: Animals; Aorta; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dronabinol; Endothelium, Vascular; Male; Niacinamide; Rats; Rats, Sprague-Dawley; Treatment Outcome; Vasodilation | 2015 |
Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic.
Topics: Amino Acid Substitution; Animals; Body Weight; Carbamates; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Dronabinol; Eating; Glucose Tolerance Test; Male; Mice, Mutant Strains; Obesity; Piperazines; Receptor, Cannabinoid, CB1 | 2016 |
The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells.
Topics: Animals; Brain; Cell Proliferation; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Dronabinol; Female; Mice; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Rats | 2007 |
Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relationship, Drug; Down-Regulation; Dronabinol; Drug Synergism; Drug Therapy, Combination; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Mice; Mice, Inbred ICR; Morphine; Opioid Peptides; Pain Measurement; Pain Threshold; Rats; Rats, Sprague-Dawley | 2008 |
Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes.
Topics: Animals; Autoimmune Diseases; B-Lymphocytes; CD3 Complex; Cytokines; Diabetes Mellitus, Experimental; Dronabinol; Immunosuppressive Agents; Lymphocyte Activation; Male; Mice; RNA, Messenger; Streptozocin | 2001 |